ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 285 filers reported holding ROYALTY PHARMA PLC in Q2 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $73,765,515 | +30.3% | 2,797,327 | +50.1% | 0.02% | +5.0% |
Q1 2024 | $56,601,265 | +35.8% | 1,863,723 | +25.6% | 0.02% | +25.0% |
Q4 2023 | $41,691,318 | +14.1% | 1,484,205 | +10.2% | 0.02% | 0.0% |
Q3 2023 | $36,545,666 | -12.3% | 1,346,561 | +16.4% | 0.02% | -20.0% |
Q2 2023 | $41,686,711 | 0.0% | 1,157,000 | 0.0% | 0.02% | 0.0% |
Q1 2023 | $41,686,711 | -3.3% | 1,157,000 | +6.1% | 0.02% | -13.0% |
Q4 2022 | $43,104,505 | -99.9% | 1,090,701 | +6.0% | 0.02% | 0.0% |
Q3 2022 | $41,361,573,000 | +5.0% | 1,029,407 | +9.9% | 0.02% | +9.5% |
Q2 2022 | $39,375,337,000 | +7.7% | 936,616 | -0.2% | 0.02% | +31.2% |
Q1 2022 | $36,559,323,000 | +0.2% | 938,381 | +2.5% | 0.02% | +14.3% |
Q4 2021 | $36,489,928,000 | +71.1% | 915,682 | +55.2% | 0.01% | +55.6% |
Q3 2021 | $21,327,624,000 | -9.3% | 590,139 | +2.9% | 0.01% | -10.0% |
Q2 2021 | $23,505,102,000 | +4.0% | 573,435 | +10.7% | 0.01% | 0.0% |
Q1 2021 | $22,593,152,000 | – | 517,954 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $263,446,000 | 59.92% |
Memorial Sloan Kettering Cancer Center | 1,128,255 | $43,957,000 | 50.90% |
Vantage Consulting Group Inc | 2,727,854 | $106,277,000 | 41.47% |
Indie Asset Partners, LLC | 756,874 | $29,488,000 | 22.15% |
Overbrook Management Corp | 723,250 | $28,178,000 | 6.25% |
Brown University | 621,759 | $24,224,000 | 5.93% |
Geo Capital Gestora de Recursos Ltd | 200,692 | $8,527,000 | 3.82% |
Lagoda Investment Management, L.P. | 141,560 | $5,515,000 | 2.97% |
Greytown Advisors Inc. | 131,143 | $5,109,000 | 2.47% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,025,610 | $78,918,000 | 2.41% |